Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy-Reference-Cited by-同舟云学术

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

Published:2017-11-23 Issue:21 Volume:130 Page:2295-2306
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Hay Kevin A.¹²^ORCID,Hanafi Laïla-Aïcha¹,Li Daniel³,Gust Juliane⁴,Liles W. Conrad⁵^ORCID,Wurfel Mark M.⁵,López José A.⁵⁶^ORCID,Chen Junmei⁶,Chung Dominic⁶,Harju-Baker Susanna⁵^ORCID,Cherian Sindhu⁷,Chen Xueyan⁷,Riddell Stanley R.¹⁵^ORCID,Maloney David G.¹⁵^ORCID,Turtle Cameron J.¹⁵^ORCID

Affiliation:

1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;

2. Department of Medicine, University of British Columbia, Vancouver, BC, Canada;

3. Juno Therapeutics, Seattle, WA;

4. Seattle Children’s Hospital, Seattle, WA;

5. Department of Medicine, University of Washington, Seattle, WA;

6. Bloodworks Northwest, Seattle, WA; and

7. Department of Laboratory Medicine, University of Washington, Seattle, WA

Abstract

Key Points Characterization of the kinetics and risk factors for severe CRS after CD19 CAR T cells will facilitate preemptive therapy and management. Severe CRS is characterized by endothelial activation.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/21/2295/1403588/blood793141.pdf

Reference32 articles.

1. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells;Turtle;Sci Transl Med,2016

2. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients;Turtle;J Clin Invest,2016

3. CD19 CAR-T cells are highly effective in ibrutinib-refractory chronic lymphocytic leukemia [abstract];Turtle;Blood,2016

4. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia;Grupp;N Engl J Med,2013

5. Chimeric antigen receptor T cells for sustained remissions in leukemia;Maude;N Engl J Med,2014

Cited by 750 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines;Blood Advances;2024-02-13

2. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001;Blood;2024-02-01

3. Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time;Frontiers in Immunology;2024-01-22

4. Mechanical forces amplify TCR mechanotransduction in T cell activation and function;Applied Physics Reviews;2024-01-19

5. Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies;Journal of Biomedical Science;2024-01-12